2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

(PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-142059
    PDE5-IN-4
    		Inhibitor 99.60%
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure.
    PDE5-IN-4
  • HY-152106
    BAY-7081
    		Inhibitor 99.03%
    BAY-7081 is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC50 of 15 nM.
    BAY-7081
  • HY-B0809S
    Theophylline-d6
    		Inhibitor 99.90%
    Theophylline-d6 is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.
    Theophylline-d<sub>6</sub>
  • HY-164368
    GLUT4 activator 2
    		Activator
    GLUT4 activator 2 (C59) is an insulin sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation.
    GLUT4 activator 2
  • HY-B0004S
    Doxofylline-d6
    		Inhibitor ≥99.0%
    Doxofylline-d6 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV.
    Doxofylline-d<sub>6</sub>
  • HY-N7272
    Cirsimarin
    		Inhibitor 99.71%
    Cirsimarin is a potent antilipogenic flavonoid isolated from Microtea debilis. Cirsimarin exerts potent antilipogenic effect and decreases adipose tissue deposition in mice. The lipolytic activity of Cirsimarin resulting from both its antagonist activity on adenosin A1 receptor and its inhibitory effect on phosphodiesterase.
    Cirsimarin
  • HY-106230A
    Dasantafil
    		Inhibitor 98.35%
    Dasantafil (SCH-446132) is a small molecule phosphodiesterase-5A (PDE5A) inhibitor used to in genitourinary disorders and study erectile dysfunction.
    Dasantafil
  • HY-B0523
    Anagrelide
    		Inhibitor 99.87%
    Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action.
    Anagrelide
  • HY-115555
    K-Ras-PDEδ-IN-1
    		Inhibitor 99.62%
    K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM.
    K-Ras-PDEδ-IN-1
  • HY-12913
    AMG 579
    		Inhibitor 99.02%
    AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 of 0.1 nM.
    AMG 579
  • HY-128593
    TPN171
    		Inhibitor 98.10%
    TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).
    TPN171
  • HY-124768
    PDE12-IN-3
    		Inhibitor 98.02%
    PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC50 of 7.68. Antiviral activity.
    PDE12-IN-3
  • HY-12812
    Autotaxin modulator 1
    		Modulator 99.40%
    Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer.
    Autotaxin modulator 1
  • HY-133019
    ATX inhibitor 5
    		Inhibitor 99.20%
    ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.
    ATX inhibitor 5
  • HY-90009C
    ent-Tadalafil
    		Inhibitor 98.17%
    ent-Tadalafil (ent-IC-351), compound (6S,12aS), is a inactive cis-enantiomer of compound (6R,12aS). compound (6R,12aS) is a potent PDE5 inhibitor with an IC50 of 0.090 μM, while ent-Tadalafil is inactive at concentrations up to 10 µM.
    ent-Tadalafil
  • HY-W011336
    PDE5-IN-7
    		Inhibitor 99.59%
    PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC50 value of 5 nM, while an IC50 of 300 nM for PDE 1.
    PDE5-IN-7
  • HY-104028A
    BAY 73-6691 racemate
    		Inhibitor 99.86%
    BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.
    BAY 73-6691 racemate
  • HY-133712
    Yonkenafil
    		Inhibitor 99.52%
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil
  • HY-19672
    Lirimilast
    		Inhibitor 98.69%
    Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties.
    Lirimilast
  • HY-163343
    Enpp-1-IN-20
    		Inhibitor 98.06%
    Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC50 of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC50 of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer.
    Enpp-1-IN-20
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

PDE1

PDE2

PDE3

PDE4

PDE5

PDE6

PDE7

PDE9

PDE10

PDE11

PDE12

PDE8

Autotaxin

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Phosphodiesterase (PDE) Inhibitors, Antagonists, Activators & Modulators
Product NamePDE1PDE2PDE3PDE4PDE5PDE6PDE7PDE9PDE10PDE11PDE12PDE8AutotaxinPurity    
IBMX  
PDE3
PDE4
         99.99%
Rolipram   
PDE4
         99.45%
Roflumilast   
PDE4
         99.98%
PDE1-IN-9
PDE1C, IC50: 11 nM
            98.74%
Sildenafil    
PDE5
        99.90%
Icariin   
PDE4, IC50: 73.5 μM
PDE5, IC50: 432 nM
        99.06%
Apremilast   
PDE4, IC50: 74 nM
         99.91%
Theophylline  
PDE3
          99.94%
Milrinone  
PDE3
          99.80%
Ro 20-1724   
PDE4, Ki: 1930 nM
         99.98%
Ziritaxestat            
Autotaxin, IC50: 131 nM
Autotaxin, Ki: 15 nM
99.93%
ITI-214
PDE1, Ki: 58 pM
PDE1A, Ki: 33 pM
PDE1B, Ki: 380 pM
PDE1C, Ki: 35 pM
            99.19%
Zatolmilast   
PDE4D3, IC50: 7.4 nM
PDE4D7, IC50: 7.8 nM
         99.50%
Sildenafil citrate    
PDE5
        99.86%
Tadalafil    
PDE5
        99.92%
Crisaborole   
PDE4
         99.92%
EHNA hydrochloride 
hPDE2A, IC50: 0.8 μM
           99.61%
Bay 60-7550 
PDE2
           98.24%
PF-8380            
Autotaxin, IC50: 2.8 nM (In isolated enzyme assay)
99.05%
Butein   
PDE4, IC50: 10.4 μM
         99.95%
Cilostamide  
PDE3
          99.64%
Zaprinast    
PDE5
        99.95%
Avanafil
PDE1, IC50: 53000 nM
PDE2, IC50: 51000 nM
 
PDE4, IC50: 5700 nM
PDE5, IC50: 5.2 nM
PDE6, IC50: 630 nM
PDE7, IC50: 27000 nM
 
PDE10, IC50: 6200 nM
    98.66%
FPFT-2216     
PDE6D
       99.75%
Difamilast   
PDE4B, IC50: 11.2 nM
         99.63%
Ensifentrine  
PDE3, IC50: 0.4 nM
PDE4, IC50: 1479 nM
         99.70%
Moracin M   
PDE4D2, IC50: 2.9 μM
PDE4B2, IC50: 4.5 μM
PDE5A1, IC50: >40 μM
  
PDE9A2, IC50: >100 μM
     98.90%
HA130            
Autotaxin, IC50: 28 nM
99.46%
BRL-50481      
PDE7
      99.85%
D159687   
PDE4
         98.34%
Mardepodect        
PDE10
    99.04%
MR-L2   
PDE4
         98.63%
Balipodect        
PDE10
    99.47%
PF-05180999 
PDE2A, IC50: 1.6 nM
    
PDE7B, IC50: 50.09 μM
 
PDE10A1, IC50: 2.03 μM
PDE11A4, IC50: 26.969 μM
   99.97%
Mirodenafil dihydrochloride    
PDE5
        99.85%
Vardenafil
PDE1, IC50: 180 nM
 
PDE3, IC50: >1000 nM
PDE4, IC50: >1000 nM
PDE5, IC50: 0.7 nM
PDE6, IC50: 11 nM
       99.81%
Edelinontrine       
PDE9
     99.85%
DNMDP  
PDE3
          98.95%
BC11-38        
PDE10, IC50: >100 μM
PDE11, IC50: 0.28 μM
   99.42%
(S)-(+)-Rolipram   
PDE4, IC50: 1100 nM
         99.77%
MK-8189        
PDE10A, Ki: 29 pM
    98.95%
GSK256066   
PDE4, IC50: 3.2 pM
         98.69%
Cilomilast   
LPDE4, IC50: ~100 nM
HPDE4, IC50: 120 nM
         99.91%
BAY 2666605  
PDE3A, IC50: 87 nM
PDE3B, IC50: 50 nM
          99.74%
BI-2545            
Autotaxin
98.85%
TMX-4100     
PDE6D
       98.18%
Vardenafil hydrochloride
PDE1, IC50: 180 nM
 
PDE3, IC50: >1000 nM
PDE4, IC50: >1000 nM
PDE5, IC50: 0.7 nM
PDE6, IC50: 11 nM
       99.79%
Piclamilast
PDE1, IC50: >100 μM
PDE2, IC50: 40 μM
PDE3, IC50: >100 μM
PDE4, IC50: 16 nM (in pig aorta)
PDE4, IC50: 2 nM (in eosinophil soluble)
PDE5, IC50: 14 μM
        99.74%
PDE4B-IN-2   
PDE4B, IC50: 15 nM
PDE4D, IC50: 1.7 μM
         99.21%
TP-10        
PDE10
    99.88%
Glaucine   
PDE4
         99.57%
PF-05085727 
PDE2A, IC50: 2 nM
           99.60%
Orismilast   
PDE4B3, IC50: 3 nM
PDE4D7, IC50: 3 nM
PDE4D5, IC50: 3 nM
PDE4B2, IC50: 6 nM
PDE4D3, IC50: 8 nM
PDE4D4, IC50: 8 nM
PDE4D1, IC50: 9 nM
PDE4D2, IC50: 9 nM
PDE4A4, IC50: 11 nM
PDE4B1, IC50: 16 nM
PDE4A1, IC50: 16 nM
PDE4A10, IC50: 52 nM
PDE4C2, IC50: 104 nM
         99.37%
Zardaverine  
PDE3
PDE4
         98.64%
ONO-8430506            
Autotaxin
99.68%
PF-04449613       
PDE9A, IC50: 22 nM
     99.83%
Sp-cAMPS sodium salt  
PDE3A, Ki: 47.6 μM
     
PDE10 GAF domain, EC50: 50 μM
    99.45%
Pimobendan  
PDE3
          99.82%
Mirodenafil    
PDE5
        99.70%
Fenspiride hydrochloride  
PDE3
PDE4
PDE5
        99.11%
PF-06445974   
PDE4B, IC50: <1 nM
PDE4D, IC50: 36 nM
PDE4A, IC50: 4.7 nM
PDE4C, IC50: 17 nM
         98.23%
TyK2-IN-2   
PDE4, IC50: 62 nM
         98.64%
Drotaverine hydrochloride   
PDE4
         99.65%
Roflupram   
PDE4, IC50: 26.2 nM
         99.45%
Tovinontrine
PDE1A3, : 88.4 nM
PDE1B, : 8.48 nM
PDE1C, : 12.2 nM
   
PDE5A2, : 81.9 nM
  
PDE9A1, : 8.19 nM
PDE9A2, : 9.99 nM
     99.83%
Irsogladine   
PDE4
         99.97%
Tanimilast   
PDE4, IC50: 0.026 nM
         99.49%
BRD9500  
PDE3A, IC50: 10 nM
PDE3B, IC50: 27 nM
          99.46%
Enoximone  
PDE3/PDE Ⅲ, IC50: 5.9 μM
PDE4A, IC50: 21.1 μM (myocardial PDE4A)
         99.91%
Etazolate hydrochloride   
PDE4, IC50: 2 μM
         98.00%
TMX-4113     
PDE6D
       99.08%
OR-1896  
PDE3/PDE Ⅲ
          99.03%
Lodenafil    
PDE5
        99.94%
Udenafil    
PDE5
        99.67%
TAK-915
PDE1A, IC50: 2497 nM
PDE2A, IC50: 0.61 nM
           99.74%
BAY 73-6691       
PDE9
     99.84%
Autotaxin-IN-3            
Autotaxin, IC50: 2.4 nM
98.24%
Osoresnontrine
PDE1C, IC50: 1 μM
PDE1A, IC50: 1.4 μM
      
PDE9A, IC50: 52 nM
     99.88%
PDE1-IN-2
PDE1A, IC50: 164 nM
PDE1B, IC50: 140 nM
PDE1C, IC50: 6 nM
            ≥98.0%
ML-030   
PDE4
         99.50%
(Rac)-Apremilast   
hPDE4D, IC50: 0.3 nM
         99.53%
Olprinone
PDE1, IC50: 150 μM
PDE2, IC50: 100 μM
PDE3, IC50: 0.35 μM
PDE4, IC50: 14 μM
         99.29%
DSR-141562
PDE1
            99.98%
PAT-505            
Autotaxin, IC50: 2 nM (In Hep3B cells)
Autotaxin, IC50: 9.7 nM (In human blood )
Autotaxin, IC50: 62 nM (In mouse plasma)
99.47%
CM-675    
PDE5, IC50: 114 nM nM
        99.53%
Theophylline (Standard)  
PDE3
          99.99%
Nortadalafil    
PDE5
        99.71%
Oglemilast   
PDE4D3, IC50: .5 nM
         98.00%
Vardenafil hydrochloride trihydrate
PDE1, IC50: 180 nM
 
PDE3, IC50: >1000 nM
PDE4, IC50: >1000 nM
PDE5, IC50: 0.7 nM
PDE6, IC50: 11 nM
       99.67%
PDE7-IN-3      
PDE7
      99.94%
GSK356278   
PDE4A, pIC50: 8.6
PDE4B, pIC50: 8.8
PDE4D, pIC50: 8.7
         99.82%
MY-5445   
PDE4, IC50: 37 μM
PDE5, IC50: 6.7 μM
PDE5, Ki: 1.3 μM
        99.86%
PDE9-IN-1       
PDE9A, IC50: 8.7 nM
     99.70%
K134 
PDE2
PDE3
          99.84%
PF-00489791    
PDE5A, IC50: 5 nM
        99.70%
Thioquinapiperifil dihydrochloride
PDE1, IC50: 380 nM
PDE2, IC50: 670 nM
PDE3, IC50: 38 nM
PDE4, IC50: 800 nM
PDE5, IC50: 0.074 nM
        99.22%
Mardepodect hydrochloride        
PDE10
    99.94%
PDE4B-IN-3   
PDE4B, IC50: .94 μM
         99.37%
AN3199   
PDE4, IC50: 94.5 nM
         99.76%
LEO 39652   
PDE4D, IC50: 3.8 nM
PDE4A, IC50: 1.2 nM
PDE4B, IC50: 1.2 nM
PDE4C2, IC50: 3.0 nM
         99.51%
Dovramilast   
PDE4
PDE4
         99.83%
N-Methylbenzamide        
PDE10A
    99.93%
Motapizone  
PDE3
          
Robustine    
PDE5A
        99.97%
CI-1044   
PDE4A5, IC50: 0.29 μM
PDE4B2, IC50: 0.08 μM
PDE4C2, IC50: 0.56 μM
PDE4D3, IC50: 0.09 μM
         98.02%
Sildenafil-d3    
PDE5
        99.79%
Hcyb1 
PDE2
           98.20%
PDE5-IN-4    
PDE5
        99.60%
BAY-7081       
PDE9A, IC50: 15 nM
     99.03%
K-Ras-PDEδ-IN-1   
PDE4, Kd: 8.3 nM
         99.62%
TPN171    
PDE5, IC50: 0.62 nM
        98.10%
PDE12-IN-3          
PDE12, pXC50: 7.68
  98.02%
Autotaxin modulator 1            
Autotaxin
99.40%
ATX inhibitor 5            
Autotaxin
99.20%
ent-Tadalafil    
PDE5, IC50: 10 μM
        98.17%
PDE5-IN-7
PDE1, IC50: 300 nM
   
PDE5, IC50: 5 nM
        99.59%
Lirimilast   
PDE4, IC50: 42 nM
         98.69%
MBCQ
PDE Ⅰ, IC50: >100 μM
PDE Ⅱ, IC50: >100 μM
PDE Ⅲ, IC50: >100 μM
PDE Ⅳ, IC50: >100 μM
PDE V, IC50: 19 nM
        99.80%
THPP-1        
PDE10
    98.75%
Carbodenafil    
PDE5
        99.63%
Sp-cAMPS  
PDE3A, Ki: 47.6 μM
     
PDE10 GAF domain, EC50: 50 μM
    
PDE7-IN-2      
PDE7A, IC50: 2.1 μM
      ≥99.0%
PQ-10        
PDE10A, IC50: 4.6 nM
    99.77%
MK-0952   
PDE4, IC50: 0.53 nM
         99.71%
Ayanin 
PDE2A
 
PDE4
         98.18%
Gisadenafil besylate
PDE1A, IC50: 9.1 μM
   
PDE5A, IC50: 3.6 nM
        ≥99.0%
PF-8380 hydrochloride            
Autotaxin, IC50: 2.8 nM (In isolated enzyme assay)
98.59%
Tetomilast   
PDE4
         ≥98.0%
PDE10A-IN-2 hydrochloride        
PDE10A, IC50: 2.8 nM
    98.43%
PDE12-IN-1          
PDE12, pIC50: 9.1
  98.85%
PDE2/PDE10-IN-1 
hPDE2A, IC50: 29 nM
 
hPDE4D, IC50: 5890 nM
    
rPDE10A, IC50: 480 nM
hPDE11A, IC50: 6920 nM
   99.88%
FCPR03   
PDE4 catalytic domain, IC50: 60 nM
PDE4B1, IC50: 31 nM
PDE4D7, IC50: 47 nM
         99.82%
BIO-32546            
Autotaxin
99.05%
Olprinone Hydrochloride  
PDE3
          99.85%
RS-25344 hydrochloride
PDE Ⅰ, IC50: >100 μM
PDE Ⅱ, IC50: 160 μM
PDE Ⅲ, IC50: 330 μM
PDE Ⅳ, IC50: 0.28 nM
         99.93%
Atizoram   
PDE4
         
BW-A 78U   
PDE4, IC50: 3 μM
         99.67%
PDE4-IN-4   
PDE4
         
Acetildenafil    
PDE5
        ≥99.0%
Kuraridine    
PDE5, IC50: 0.64 μM
        ≥98.0%
Lodenafil carbonate    
PDE5
        ≥98.0%
Yonkenafil hydrochloride    
PDE5
        99.43%
Sophoflavescenol    
PDE5
        98.78%
EMD 53998  
PDE3
          99.59%
Apremilast-d5   
PDE4
         98.63%
PDE10-IN-1        
PDE10
    99.44%
T-0156
PDE1, IC50: >100 μM
PDE2, IC50: >100 μM
PDE3, IC50: >100 μM
PDE4, IC50: 63 μM
PDE5, IC50: 0.23 nM
PDE6, IC50: 56 nM
       
S32826 disodium            
Autotaxin, IC50: 8.8 nM
98.85%
CDC801   
PDE4
         98.94%
ITI-214 free base
PDE1, Ki: 58 pM
PDE1A, Ki: 33 pM
PDE1B, Ki: 380 pM
PDE1C, Ki: 35 pM
            ≥98.0%
PF-07038124   
PDE4B2, IC50: 0.5 nM
         
LASSBio-1632   
PDE4A
PDE4D
         
PF-04822163
PDE1A, IC50: 2 nM
PDE1B, IC50: 2.4 nM
PDE1C, IC50: 7 nM
PDE2A, IC50: 5895 nM
PDE3A, IC50: >30000 nM
PDE4D3, IC50: 7620 nM
PDE5A1, IC50: >30000 nM
 
PDE7B, IC50: >29800 nM
PDE9A1, IC50: >30000 nM
PDE10A1, IC50: 252 nM
PDE11A4, IC50: 8257 nM
   
Vardenafil dihydrochloride
PDE1, IC50: 180 nM
   
PDE5, IC50: 0.7 nM
PDE6, IC50: 11 nM
       
Avanafil dibenzenesulfonate
PDE1, IC50: 53000 nM
PDE2, IC50: 51000 nM
 
PDE4, IC50: 5700 nM
PDE5, IC50: 5.2 nM
PDE6, IC50: 630 nM
PDE7, IC50: 27000 nM
 
PDE10, IC50: 6200 nM
    
TPN729MA
PDE1, IC50: 566 nM
  
PDE4, IC50: 834 nM
PDE5, IC50: 2.28 nM
PDE6, IC50: 45.2 nM
   
PDE11, IC50: 6090 nM
   99.45%
TPN729
PDE1, IC50: 566 nM
  
PDE4, IC50: 834 nM
PDE5, IC50: 2.28 nM
PDE6, IC50: 45.2 nM
   
PDE11, IC50: 6090 nM
   
Autotaxin-IN-4            
Autotaxin
PDE5-IN-2 
PDE2A, IC50: 106 nM
 
PDE4D2, IC50: 43 nM
PDE5A1, IC50: 0.31 nM
PDE6C, IC50: 1.2 nM
  
PDE10A, IC50: 46 nM
    
Theophylline monohydrate  
PDE3
          
MT-3014        
human PDE 10A, IC50: 0.062 nM
bovine PDE 10A, IC50: 0.09 nM
    
ID11916    
PDE5
        
Sp-cAMPS triethylamine  
PDE3A, Ki: 47.6 μM
     
PDE10 GAF domain, EC50: 50 μM
    
PDE10A-IN-5        
PDE10A, IC50: 3.5 nM
    
(S)-C33
PDE1B, IC50: 554 ± 64 nM
PDE2A, IC50: 2.4 ± 0.5 μM
 
PDE4D2, IC50: 1.3 ± 0.1 μM
PDE5A1, IC50: 366 ± 38 nM
  
PDE9A, IC50: 11 ± 4 nM
PDE10A1, IC50: 2.3 ± 0.3 μM
    99.46%
Menabitan dihydrochloride       
PDE9
     
P7–2302   
PDE4B, IC50: 77.3 nM
  
PDE7, IC50: 0.18 nM
      
Gemlapodect        
PDE10A
    
PDE11-IN-1         
PDE11
   98.23%
PDE4-IN-6   
PDE4B, IC50: 0.125 μM
PDE4D, IC50: 0.43 μM
         
PDE4-IN-15   
PDE4
         
Meribendan  
PDE Ⅲ
          
Thioquinapiperifil
PDE1, IC50: 380 nM
PDE2, IC50: 670 nM
PDE3, IC50: 38 nM
PDE4, IC50: 800 nM
PDE5, IC50: 0.074 nM
        
Deltazinone 1     
PDEδ, Kd: 8 nM
       
PDE11A4-IN-1         
PDE11A4, IC50: 12 nM
   
S32826            
Autotaxin, IC50: 8.8 nM
PDE5-IN-3    
PDE5, IC50: 1.57 nM
        
Imazodan hydrochloride  
PDE3/PDE Ⅲ
          
PDE5-IN-13
PDE1C, IC50: 10478 nM
PDE2A, IC50: 3378 nM
PDE3A, IC50: >100000 nM
PDE4D2, IC50: 53294 nM
PDE5A, IC50: 3 nM
PDE6C, IC50: 20 nM
PDE7A, IC50: 25746 nM
PDE9A2, IC50: >100000 nM
PDE10A2, IC50: 21160 nM
PDE11A, IC50: >100000 nM
 
PDE8A1, IC50: >100000 nM
 
Z21090   
PDE4, IC50: 37.4 nM
         
Menabitan       
PDE9
     
PDE4B/D-IN-3   
PDE4B, IC50: 0.071 nM
PDE4D, IC50: 0.09 nM
         
PDE4-IN-24   
PDE4D, IC50: 0.57 nM
         
PF-03049423 free base    
PDE5A
        
ATX inhibitor 18            
Autotaxin, IC50: 24.2 nM
PDE4-IN-12   
PDE4D2, IC50: 3.51 nM
PDE4B2, IC50: 9.51 nM
PDE5A1, IC50: 1.24 μM
 
PDE7A, IC50: 15 nM
 
PDE10A, IC50: 1.02 μM
  
PDE8A1, IC50: 194 nM
 
FR-229934    
PDE V
        98.65%
Gisadenafil
PDE1A, IC50: 9.1 μM
   
PDE5A, IC50: 3.6 nM
        
(R)-Irsenontrine       
PDE9, IC50: 0.041 μM
     99.00%
PDE5-IN-9    
PDE5
        ≥98.0%
PDE4B-IN-4   
PDE4B, IC50: 2.82 nM
         
Tofimilast   
PDE4, IC50: 0.14 μM
         
ATX inhibitor 20            
Autotaxin, IC50: 2.3 ± 0.31 nM
ATX inhibitor 15            
Autotaxin, IC50: 2.17 nM
PDE5/HDAC-IN-1    
PDE5, IC50: 46.3 nM
        
Norbraylin   
PDE4D2, IC50: 7.15 μM
         
PDE4-IN-18   
PDE4, IC50: 1.55 μM
         
ATX inhibitor 12            
Autotaxin, IC50: 1.72 nM
PDE4-IN-26   
PDE4A, IC50: 89.7 nM
PDE4B, IC50: 48.8 nM
PDE4D, IC50: 5.9 nM
         
Anagrelide hydrochloride monohydrate  
PDE3
          
ICI-63197
PDE Ⅰ, Ki: 487 μM
PDE Ⅱ, Ki: >1000 μM
PDE3/PDE Ⅲ, Ki: 9 μM
PDE Ⅳ, Ki: 10 μM
         99.14%
PDE3B-IN-1  
PDE3B, IC50: 6.5 μM
          
PDE4B/D-IN-4   
PDE4B, IC50: 5.50 nM
PDE4D, IC50: 6.81 nM
         
PDE4-IN-11   
PDE4
         
Phosphodiesterase-IN-2        
PDE10A, IC50: 11.9 nM
    
ATX inhibitor 19            
Autotaxin, IC50: 156 ± 19.8 nM
ATX inhibitor 14            
Autotaxin, IC50: 0.41 nM
PDE2A-IN-1 
PDE2
           
Arofylline   
PDE4
         
Ilexsaponin B2
PDEI, IC50: 477.5 μM
   
PDE5, IC50: 48.8 μM
        
Autotaxin-IN-1            
Autotaxin, IC50: 2 nM
ATX inhibitor 8            
Autotaxin
BC8-15   
PDE4A, IC50: 0.22 μM
  
PDE7A, IC50: 6.46 μM
    
PDE8A, IC50: 0.28 μM
 
PDE7A-IN-1      
PDE7A, IC50: 3.7 nM
      
Icariin (Standard)   
PDE4
PDE5
        
Z19153   
PDE4B1, IC50: 110 nM
PDE4D7, IC50: 1160 nM
         
PDE4B/D-IN-2   
PDE4B, IC50: 0.023 nM
PDE4D, IC50: 0.066 nM
         
MK-0873   
PDE4
         
AGS-16C3F  
PDE3
          
PDE5-IN-10    
PDE5, IC50: 20 nM
        
JNJ-42314415        
human PDE 10A, Ki: 35 nM
    
1,3,5-Trihydroxy-4-prenylxanthone    
PDE5, IC50: 3 μM
        
PDE4B/D-IN-1   
PDE4B, IC50: 0.07 nM
PDE4D, IC50: 0.09 nM
         
Mesembrine   
PDE4B, IC50: 7.8 μM
         
12-epi-Tadalafil    
PDE5, IC50: 0.09 μM
        
PDE1-IN-7
PDEI, IC50: 10 nM
            
CDP-840   
PDE4
         
Autotaxin-IN-5            
Autotaxin
Fenspiride  
PDE3
PDE4
PDE5
        
PDE4D inhibitor 1
PDE1B2, IC50: >10000 nM
PDE2A, IC50: >10000 nM
PDE3A, IC50: >10000 nM
PDE4B1, IC50: 5.3 nM
PDE4D2, IC50: 8.6 nM
PDE4A10, IC50: 100 nM
PDE4C1, IC50: 747 nM
PDE5A1, IC50: 1730 nM
 
PDE7A1, IC50: 5913 nM
PDE9A2, IC50: >10000 nM
PDE10A2, IC50: 1953 nM
  
PDE8A1, IC50: >10000 nM
 
PDE4-IN-5   
PDE4
         
Autotaxin-IN-6            
Autotaxin, IC50: 30 nM
MHC00188            
Autotaxin
ATX inhibitor 11            
Autotaxin, IC50: 2.7 ± 1 nM
PDE4-IN-8   
PDE4B2, IC50: 0.93 nM
         
Avanafil-13C,d3
PDE1
            
Mesopram   
PDE4
         98.80%
Deacetylsclerotiorin   
PDE4, IC50: 2.8 μM
         
Theophylline sodium acetate  
PDE3
          
PDE4-IN-13   
PDE4, IC50: 1.56 μM
         
Talaroterphenyl A   
PDE4, IC50: 1.2 μM
         
TC-E 5005 
PDE2A, IC50: 239 nM
PDE3A, IC50: 3700 nM
 
PDE5A, IC50: 919 nM
 
PDE7B, IC50: 3100 nM
 
PDE10A, IC50: 7.28 nM
hPDE11A, IC50: 779 nM
   
PDE4B/7A-IN-1   
PDE4
  
PDE7
      
AChE/PDE4-IN-1   
PDE4, IC50: 1.88 μM
         
PDE4B/7A-IN-2   
PDE4
  
PDE7
      
PDE5-IN-5    
PDE5, IC50: 2.0 nM
        
ATX inhibitor 21            
Autotaxin, IC50: 3490 ± 170 nM
Z21115   
PDE4D7, IC50: 10.5 nM
PDE4D, IC50: 65.7 nM
PDE4B, IC50: 64.4 nM
         
L-869298   
PDE4A, IC50: 0.5 nM
         
PF-07038124 hydrochloride   
PDE4, : 0.5 nM
         
PDE5-IN-12    
PDE5, IC50: 22 nM
        
PF-03049423    
PDE5A
        
PDE1-IN-4
PDE1C, IC50: 10 ± 3 nM
PDE1A, IC50: 145 nM
PDE1B, IC50: 354 nM
PDE2A, IC50: 5130 nM
PDE3A, IC50: >10000 nM
PDE4B2, IC50: 619 nM
PDE4D2, IC50: 948 nM
PDE5A1, IC50: 1810 nM
  
PDE9A2, IC50: >10000 nM
PDE10A, IC50: 1310 nM
    
PDE4-IN-19   
PDE4B1, IC50: <10 nM
PDE4D3, IC50: 10-100 nM
         
PDE4-IN-10   
PDE4B, IC50: 7.01 ± 1.0 μM
         
PDE1-IN-8
PDE1C, IC50: 11 nM
PDE1A, IC50: 263 nM
PDE1B, IC50: 357 nM
PDE2A, IC50: 1820 nM
PDE3A, IC50: 5164 nM
PDE4D, IC50: 3006 nM
PDE5A, IC50: 681 nM
 
PDE7A, IC50: 2093 nM
PDE9A, IC50: 4617 nM
PDE10A, IC50: 2394 nM
  
PDE8A, IC50: 3729 nM
 
Pumafentrine  
PDE3
PDE4
         
SAR156497  
PDE3, IC50: 4 μM
          
ATX inhibitor 22            
Autotaxin, IC50: 218 nM
CP-220629   
PDE4, IC50: 0.44 μM
         
AMG580        
PDE10A
    
UK-500001   
PDE4D3, IC50: 0.28 nM
PDE4B2, IC50: 22.8 nM
PDE4A4, IC50: 26.1 nM
PDE4C2, IC50: 217 nM
         
MEY-003            
Autotaxin
N-Desethyl-N-methyl vardenafil    
PDE5, IC50: 0.14 μM
        
Xanthoanthrafil    
PDE5, : 3.95 ng/mL
        
SCH 51866
PDE1, IC50: 70 nM
   
PDE5, IC50: 60 nM
        
CM-545    
PDE5, pIC50: 7.47
        
AWD 12-281   
PDE4, IC50: 9.7 nM
         
RS14203   
PDE4
         
BML-288 
PDE2, IC50: 40 nM
           
UK 357903    
PDE5, IC50: 1.7 nM
PDE6, IC50: 714 nM
       
PDE4-IN-25   
PDE4, IC50: 0.1 μM
         
LEO 29102   
PDE4, IC50: 5 nM
         
Irsogladine maleate   
PDE4
         
PF-06815189 
PDE2A, IC50: 0.4 nM
           
ONO-6126   
PDE4
         
SCH 351591   
PDE4, IC50: 58 nM
         
JNJ-10258859
PDE1, Ki: >100 μM
PDE2, Ki: 25.33±5.53 μM
PDE3, Ki: 9.67±1.95 μM
PDE4, Ki: 5.01±1.88 μM
PDE5, Ki: 0.23±0.03 nM
        
MMPX
PDEI
            
BMS-341400 mesylate    
PDE5, IC50: 0.3 nM
        
L791943   
PDE4